Skip to main content
. Author manuscript; available in PMC: 2023 Mar 17.
Published in final edited form as: Cancer Treat Res Commun. 2020 Dec 13;26:100286. doi: 10.1016/j.ctarc.2020.100286

Figure 1 |. STK11 loss results in loss of type II pneumocyte identity ex vivo.

Figure 1 |

(a-f) Log2 transformed expression of NKX2-1 mRNA. (a) Cancer Cell Line Encyclopedia (CCLE) lung adenocarcinoma cell lines predicted with the STK11 loss signature cutoff WT (n = 29) < 0 > Mutant (n = 15). (b) Patient derived xenograft (PDX) models predicted with the STK11 loss signature with a cutoff of WT (n=29) < 0, Mutant (n =10) > 0.1. (c) Mouse model 1 (MM1) of n=9 KRAS tumors vs n=9 KRAS/STK11 tumors. (d) Mouse model 2 (MM2) of n=8 KRAS/TP53 tumors and n=6 STK11/PTEN tumors. (e) MLOS lung adenocarcinoma patient tumors predicted for STK11 status with WT (n=297) and Mutant (n=145). (f) TCGA lung adenocarcinoma patient tumors predicted for STK11 status with WT (n=337) and Mutant (n=178).